Health Catalyst Inc’s recently made public that its Officer Benjamin Landry acquired Company’s shares for reported $11831.0 on Jun 02 ’25. In the deal valued at $3.63 per share,3,255 shares were bought.
Then, Kevin Freeman bought 4,747 shares, generating $17,254 in total proceeds.
Before that, Daniel LeSueur bought 3,802 shares. Health Catalyst Inc shares valued at $13,820 were divested by the Officer at a price of $3.63 per share.
Evercore ISI downgraded its Health Catalyst Inc [HCAT] rating to an In-line from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including KeyBanc Capital Markets’s analysts, who increased its forecast for the stock in early January from “a Sector weight” to “an Overweight”. KeyBanc Capital Markets also remained covering HCAT and has decreased its forecast on April 10, 2024 with a “Sector weight” recommendation from previously “an Overweight” rating. Evercore ISI revised its rating on January 03, 2024. It rated HCAT as “an Outperform” which previously was an “an In-line”.
Price Performance Review of HCAT
On Monday, Health Catalyst Inc [NASDAQ:HCAT] saw its stock fall -0.26% to $3.79. Over the last five days, the stock has gained 3.84%. Health Catalyst Inc shares have fallen nearly -46.39% since the year began. Nevertheless, the stocks have fallen -42.05% over the past one year. While a 52-week high of $9.24 was reached on 01/06/25, a 52-week low of $3.49 was recorded on 05/29/25. SMA at 50 days reached $4.04, while 200 days put it at $6.25.
Levels Of Support And Resistance For HCAT Stock
The 24-hour chart illustrates a support level at 3.61, which if violated will result in even more drops to 3.44. On the upside, there is a resistance level at 3.89. A further resistance level may holdings at 4.00. The Relative Strength Index (RSI) on the 14-day chart is 44.47, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.00%. Stochastics %K at 22.93% indicates the stock is a holding.
The most recent change occurred on January 03, 2024 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $14 price target.
